news desk Lord, save her
in Monitoring of Carbapenemase (CPO) Producing Organisms discovered in Denmark, Statens Serum Institut (SSI) detected two more cases of multi-resistant bacteria in patients treated with the drug Dicillin.
In addition, traces of CPO-specific multi-resistant bacteria were found in 12 other patients, eight of whom were confirmed to have been treated with dycillin in the period prior to the discovery. The remaining four cases are still under investigation.
Thus, the outbreak of the bacterial strain now includes a total of 25 cases, where 11 cases were previously identified.
The case of multi-resistant bacteria and the drug Dicillin began when, in October 2022, SSI recorded an increase in CPO’s own multi-resistant bacteria that had not been seen before. On closer examination, the increase in bacteria could not be related to hospital infections or travel abroad, but was discovered last month on the surface of Dicillin medication capsules. As it turned out, all patients took the drug until the bacteria were detected.
SSI is following the outbreak closely and the Danish Medicines Agency is working with the manufacturer to uncover the causes of the outbreak.
None of the Danish patients became seriously ill from the bacteria, just as no further treatment for the bacteria had to be started.
Subscribe to Outbreak News TV on YouTube
“This is nothing serious for the individual patient, but we must of course do what we can to avoid the spread of multi-resistant bacteria,” SSI Professional Director Tyra Groff-Krause said. He says and continues:
“We know that most CPO bacteria have the ability to share their resistance with other bacterial species, so this part is not very surprising.”
